Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$21.71 -0.1%	$18.02	$13.40 ▼ $25.23	$3.63B	0.65	1.94 million shs	1.15 million shs
ACLX Arcellx	$66.00 -0.8%	$62.01	$47.86 ▼ $107.37	$3.64B	0.28	605,477 shs	506,811 shs
AVDL Avadel Pharmaceuticals	$9.57 +2.5%	$8.80	$6.38 ▼ $17.30	$925.79M	1.45	1.26 million shs	1.46 million shs
MRUS Merus	$54.61 -1.4%	$46.42	$33.19 ▼ $62.98	$3.78B	1.04	748,534 shs	711,649 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	-0.14%	-1.23%	+26.52%	+24.06%	+41.25%
ACLX Arcellx	-0.77%	-3.08%	+11.83%	-7.92%	+19.87%
AVDL Avadel Pharmaceuticals	+2.46%	-1.54%	+12.19%	+14.89%	-37.12%
MRUS Merus	-1.41%	-2.85%	+35.17%	+15.94%	-3.62%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	3.3858 of 5 stars	3.3	1.0	3.9	4.2	1.3
ACLX Arcellx	2.612 of 5 stars	3.5	3.0	2.8	2.5	0.0
AVDL Avadel Pharmaceuticals	2.3193 of 5 stars	3.5	1.0	3.4	1.7	0.6
MRUS Merus	3.0644 of 5 stars	4.6	3.0	2.1	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.69	Moderate Buy	$26.79	23.38% Upside
ACLX Arcellx	3.07	Buy	$111.33	68.69% Upside
AVDL Avadel Pharmaceuticals	3.00	Buy	$18.17	89.83% Upside
MRUS Merus	3.13	Buy	$85.83	57.18% Upside

Current Analyst Ratings Breakdown

Latest AVDL, MRUS, ACAD, and ACLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$26.00 ➝ $30.00
6/5/2025	ACAD ACADIA Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/5/2025	ACAD ACADIA Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Hold	$18.00 ➝ $23.00
5/23/2025	MRUS Merus	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00
5/21/2025	ACAD ACADIA Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$20.00 ➝ $35.00
5/20/2025	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $24.00
5/19/2025	ACAD ACADIA Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$28.00 ➝ $31.00
5/19/2025	ACAD ACADIA Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$20.00 ➝ $23.00
5/19/2025	ACAD ACADIA Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$26.00 ➝ $26.00
5/19/2025	ACAD ACADIA Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$24.00 ➝ $28.00
5/19/2025	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00 ➝ $30.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$996.28M	3.65	N/A	N/A	$2.63 per share	8.25
ACLX Arcellx	$76.81M	47.35	N/A	N/A	$9.97 per share	6.62
AVDL Avadel Pharmaceuticals	$194.45M	4.76	N/A	N/A	$0.98 per share	9.77
MRUS Merus	$54.73M	69.06	N/A	N/A	$6.17 per share	8.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	-$61.29M	$1.37	27.83	28.57	N/A	13.83%	25.83%	14.71%	8/5/2025 (Estimated)
ACLX Arcellx	-$70.69M	-$2.99	N/A	N/A	N/A	-25.94%	-8.28%	-5.21%	8/14/2025 (Estimated)
AVDL Avadel Pharmaceuticals	-$160.28M	-$0.27	N/A	159.50	N/A	-52.53%	-93.34%	-44.77%	8/6/2025 (Estimated)
MRUS Merus	-$154.94M	-$4.08	N/A	N/A	N/A	-680.61%	-38.89%	-31.16%	7/30/2025 (Estimated)

Latest AVDL, MRUS, ACAD, and ACLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MRUS Merus	-$1.17	-$1.40	-$0.23	-$1.40	$7.82 million	$26.49 million
5/8/2025	Q1 2025	ACLX Arcellx	-$0.84	-$1.13	-$0.29	-$1.13	$19.51 million	$8.13 million
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million
5/7/2025	Q1 2025	AVDL Avadel Pharmaceuticals	-$0.07	-$0.05	+$0.02	-$0.05	$50.57 million	$52.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ACLX Arcellx	N/A	N/A	N/A	N/A	N/A
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.29	2.11
ACLX Arcellx	N/A	4.29	4.29
AVDL Avadel Pharmaceuticals	N/A	2.97	2.60
MRUS Merus	N/A	8.32	8.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
ACLX Arcellx	96.03%
AVDL Avadel Pharmaceuticals	69.19%
MRUS Merus	96.14%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.50%
ACLX Arcellx	8.35%
AVDL Avadel Pharmaceuticals	4.80%
MRUS Merus	4.57%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	119.30 million	Optionable
ACLX Arcellx	80	55.11 million	50.70 million	Optionable
AVDL Avadel Pharmaceuticals	70	96.74 million	91.74 million	Optionable
MRUS Merus	37	69.21 million	65.34 million	Optionable

AVDL, MRUS, ACAD, and ACLX Headlines

Recent News About These Companies

Net Worth Advisory Group Buys Shares of 5,054 Merus (NASDAQ:MRUS)

June 14 at 4:50 AM | marketbeat.com

Harbor Capital Advisors Inc. Has $2.71 Million Stake in Merus (NASDAQ:MRUS)

June 12 at 4:51 AM | marketbeat.com

Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus

June 11 at 9:23 PM | seekingalpha.com

Merus’s Strategic Advancements and Promising Trials Justify Buy Rating with $92 Price Target

June 10, 2025 | tipranks.com

Underappreciated Potential of Merus’s Petosemtamab in Colorectal Cancer: Analyst Highlights Future Opportunities and Financial Stability

June 9, 2025 | tipranks.com

Why Merus N.V. (MRUS) Crashed On Wednesday

June 5, 2025 | msn.com

Why Merus N.V. (MRUS) Crashed On Wednesday

June 5, 2025 | insidermonkey.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 14,544 Shares of Merus (NASDAQ:MRUS)

June 5, 2025 | marketbeat.com

Bank of America Corp DE Has $1.59 Million Stock Position in Merus (NASDAQ:MRUS)

June 5, 2025 | marketbeat.com

Merus (NASDAQ:MRUS) Shares Gap Down - What's Next?

June 4, 2025 | marketbeat.com

Merus Shares Slide on Stock Offering

June 4, 2025 | marketwatch.com

Merus N.V. Announces Pricing of $300 Million Public Offering of Common Shares

June 4, 2025 | quiverquant.com

Merus N.V. Announces Pricing of Public Offering of Common Shares

June 4, 2025 | globenewswire.com

Merus NV Announces Proposed Public Offering of Common Shares | MRUS stock news

June 3, 2025 | gurufocus.com

Merus N.V. Announces Proposed Public Offering of Common Shares

June 3, 2025 | globenewswire.com

Merus (NASDAQ:MRUS) Sets New 52-Week High - Should You Buy?

June 3, 2025 | marketbeat.com

'Our data is resonating far more with the people that matter,' Bicara CEO says amid Merus race

June 2, 2025 | fiercebiotech.com

Bicara Responds to Rival Merus With Early Survival Data at #ASCO25

June 2, 2025 | biospace.com

Merus’s Strong Clinical Data and Financial Stability Justify Buy Rating

June 2, 2025 | tipranks.com

Squarepoint Ops LLC Buys New Stake in Merus (NASDAQ:MRUS)

June 2, 2025 | marketbeat.com

Merus (NASDAQ:MRUS) Shares Up 9% - What's Next?

May 30, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVDL, MRUS, ACAD, and ACLX Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$21.71 -0.03 (-0.14%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$21.68 -0.03 (-0.14%)

As of 06/13/2025 04:59 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Arcellx NASDAQ:ACLX

$66.00 -0.51 (-0.77%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$66.07 +0.07 (+0.11%)

As of 06/13/2025 07:58 PM Eastern

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Avadel Pharmaceuticals NASDAQ:AVDL

$9.57 +0.23 (+2.46%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$9.58 +0.01 (+0.10%)

As of 06/13/2025 04:44 PM Eastern

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Merus NASDAQ:MRUS

$54.61 -0.78 (-1.41%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$54.60 -0.01 (-0.01%)

As of 06/13/2025 05:54 PM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time